Lastly, qRT-PCR was performed to confirm that CXCR2, NAMPT, and CUEDC2 could potentially serve as biomarkers for the clinical diagnosis and risk evaluation of DN patients. The gene discussed is CXCR2; the disease is liver dysplastic nodule.